Navigation Links
Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
Date:10/27/2008

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

"This patent provides broad coverage of R3487/MEM 3454 and R4996/MEM 63908, further extends our leadership position in the development of nicotinic alpha-7 receptor agonists, and underscores our commitment to bring forward novel therapies for the treatment of CNS disorders," stated Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "We look forward to continuing to work with our partner Roche to advance our robust development programs for these compounds."

Memory Pharmaceuticals is currently conducting a Phase 2 trial for R3487/MEM 3454 in CIAS. The Company recently announced the completion of its Phase 1 program for R4996/MEM 63908 and that it expects to report the top-line data from that program in the fourth quarter of 2008.

About R3487/MEM 3454

R3487/MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the central nervous system. In a recently completed Phase 2a study in Alzheimer's disease patients, R3487/MEM 3454 demonstrated a statistically significant effect on multiple measures of cognition. Roche has a license to R3487/MEM 3454 for future development and commercialization.

About R4996/MEM 63908

R4996/MEM 63908 is the second compound in the Company's Nicotinic Alpha-7 Receptor Agonist Collaboration with Roche. In preclinical studies, R4996/MEM 63908 improved learning and memory in healthy and aged cognitively impaired animals. Under the terms of the agreement with Roche, Memory Pharmaceuticals is responsible for conducting Phase 1 clinical trials of this compound and Roche is responsible for later stage development and commercialization.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and, schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Stock Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity
2. Circadian Rhythm Plays Role in Memory
3. Caribou Coffee Honors Memory of One of Its Own With Amys Blend
4. Hub of fear memory formation identified in brain cells
5. Whole brain radiation increases risk of learning and memory problems in cancer patients
6. New Brain Fitness Program to Fight Memory Loss
7. Exercise May Help Prevent Age-Related Memory Loss
8. Australian over-50s walk away memory problems in world-first trial
9. Excercise May Help Prevent Age-Related Memory Loss
10. Age-related memory loss tied to slip in filtering information quickly
11. Pioneering Neurosciences Institute Sets Date for Dedication of New Facility and First-Ever International Forum on Memory and Memory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 2017 , ... Ultimate Medical Academy today announced the keynote ... March 23-25, 2017 in Tampa, and reminded educators and education leaders to submit ... Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D arm ...
(Date:1/23/2017)... ... ... and plastic balance boards have been around since at least the 1950s and are a ... first and only balance board to use a patent-pending design featuring high-pressure inflation technology and ... as well as skill-level adjustable for all ages and abilities. The board can be ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the premiere organization in North America for the scientific development, healthcare training and ... Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... However, choosing the right method is paramount to success. Selecting an inappropriate measurement ... situations where multiple persons use the same equipment. Rare or expensive substances are ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23 janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, ... ont annoncé aujourd,hui qu,ils se sont mis d,accord sur ... les parties. BMC et 3B seront autorisés à vendre ... à ResMed, et ResMed effectuera le paiement de la ... le litige de Floride entre les deux parties. Le ...
(Date:1/23/2017)... -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: ... agreement with the Children,s Hospital of Philadelphia ... US key opinion leader in the mitochondrial medicine field. ... Dr. ... research program, NVP015, in certain experimental disease models. The research ...
(Date:1/22/2017)... and ABU DHABI , Saudi Arabia ... from the US ... Hospital of the Future , at the World Economic ... of the future will be driven by big data and powered by artificial ... the panel of experts that discussed the ,Hospital of the Future, at the ...
Breaking Medicine Technology: